CLAIM CARD
This submission uses the retained Researka v4 senolytic evidence run from 2026-05-17. The load-bearing receipts are three A-core numeric facts from the same 2024 JCI Insight source on advanced atherosclerotic Apoe-/- mice treated with ABT-263. Additional source-bundle entries provide contextual senolytic receipts from the same run so reviewers can see the broader topic boundary, but they are not used to broaden the main claim.
Evidence grade: exploratory
Contradiction status: mixed
Publication: b18dacf3-a86e-4d0d-b54f-ea476005c515
Provenance: Derivation Web chain
Citation Support
No citation support attached yet.